'Difficult to diagnose' desmoid tumours: A potential role for CTNNB1 mutational analysis

Histopathology

Volumn 59, Issue 2, 2011, Pages 336-340

  Colombo, Chiara ^a   Bolshakov, Svetlana ^a   Hajibashi, Shohrae ^a,b   Lopez Terrada, Lola ^b   Wang, Wei Lien ^a   Rao, Priya ^a   Benjamin, Robert S ^a   Lazar, Alexander J ^a,b   Lev, Dina ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

catenin; CTNNB1; Desmoid tumour; Diagnostic tool; Sequencing

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN; FORMALDEHYDE; PARAFFIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; DESMOID TUMOR; DIFFERENTIAL DIAGNOSIS; DNA EXTRACTION; EXON; FEMALE; GENE AMPLIFICATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NEEDLE BIOPSY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; FIBROMATOSIS, ABDOMINAL; FIBROMATOSIS, AGGRESSIVE; HUMANS; MALE; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 80052229127     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03932.x     Document Type: Article

References (20)

1. Hosalkar HS, Fox EJ, Delaney T et al. Desmoid tumors and current status of management. Orthop. Clin. N. Am. 2006; 37; 53-63.
2. Mendenhall WM, Zlotecki RA, Morris CG et al. Aggressive fibromatosis. Am. J. Clin. Oncol. 2005; 28; 211-215.
3. Melis MV, Zagar JS, Sondak VK. Multimodality management of desmoid tumors: how important is a negative surgical margin? J. Surg. Oncol. 2008; 98; 594-602.
4. Clark SK, Phillips RKS. Desmoids in familial adenomatous polyposis. Br. J. Surg. 1996; 83; 11494-11504.
5. Amary MFC, Pauwels P, Meulemans E et al. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. Am. J. Surg. Pathol. 2007; 31; 1299-1309.
6. Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am. J. Surg. Pathol. 2005; 29; 653-659.
7. Montgomery E, Torbenson MS, Kaushal M et al. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am. J. Surg. Pathol. 2002; 26; 1296-1301.
8. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007; 51; 509-514.
9. Ng TL, Gown AM, Barry TS et al. Nuclear beta-catenin in mesenchymal tumors. Mod. Pathol. 2005; 18; 68-74.
10. Montgomery E, Folpe AL. The diagnostic value of beta-catenin immunohistochemistry. Adv. Anat. Pathol. 2005; 12; 350-356.
11. Coffin CM, Hornick JL, Zhou H et al. Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas. Am. J. Surg. Pathol. 2007; 31; 410-416.
12. Lazar AJF, Tuvin D, Hajibashi S et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am. J. Pathol. 2008; 173; 1518-1527.
13. Dômont J, Salas S, Lacroix L et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br. J. Cancer 2010; 102; 1032-1036.
14. Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am. J. Pathol. 1998; 153; 709-714.
15. Mirabelli-Primdahl L, Gryfe R, Kim H et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 1999; 59; 3346-3351.
16. Lazar AJF, Calonje E, Grayson W et al. Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. J. Cutan. Pathol. 2005; 32; 148-157.
17. Koch A, Denkhaus D, Albrecht S et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 1999; 59; 269-273.
18. Bell DA. Origins and molecular pathology of ovarian cancer. Mod. Pathol. 2005; 18; S19-S32.
19. Oliva E, Sarrio D, Brachtel EF et al. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. J. Pathol. 2006; 208; 708-713.
20. Irving JA, Catasus L, Gallardo A et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum. Pathol. 2005; 36; 605-619.